949 related articles for article (PubMed ID: 32351295)
1. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
2. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
[TBL] [Abstract][Full Text] [Related]
3. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
5. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.
Nam JY; Choe AR; Sinn DH; Lee JH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Lee JM; Chung JW; Choi SY; Lee JK; Baek SY; Lee HA; Kim TH; Yoo K
BMC Cancer; 2020 Jun; 20(1):504. PubMed ID: 32487089
[TBL] [Abstract][Full Text] [Related]
6. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
7. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
[TBL] [Abstract][Full Text] [Related]
9. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study.
Wang Q; Xia D; Bai W; Wang E; Sun J; Huang M; Mu W; Yin G; Li H; Zhao H; Li J; Zhang C; Zhu X; Wu J; Li J; Gong W; Li Z; Lin Z; Pan X; Shi H; Shao G; Liu J; Yang S; Zheng Y; Xu J; Song J; Wang W; Wang Z; Zhang Y; Ding R; Zhang H; Yu H; Zheng L; Gu W; You N; Wang G; Zhang S; Feng L; Liu L; Zhang P; Li X; Chen J; Xu T; Zhou W; Zeng H; Zhang Y; Huang W; Jiang W; Zhang W; Shao W; Li L; Niu J; Yuan J; Li X; Lv Y; Li K; Yin Z; Xia J; Fan D; Han G;
J Hepatol; 2019 May; 70(5):893-903. PubMed ID: 30660709
[TBL] [Abstract][Full Text] [Related]
10. Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma.
Shi ZX; Li CF; Zhao LF; Sun ZQ; Cui LM; Xin YJ; Wang DQ; Kang TR; Jiang HJ
Hepatobiliary Pancreat Dis Int; 2024 Aug; 23(4):361-369. PubMed ID: 37429785
[TBL] [Abstract][Full Text] [Related]
11. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
Li L; Gou CY; Li JY; Achakzai R; Li XH
Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
13. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma.
Li L; Kan X; Zhao Y; Liang B; Ye T; Yang L; Zheng C
Int J Med Sci; 2021; 18(11):2276-2284. PubMed ID: 33967603
[No Abstract] [Full Text] [Related]
14. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
15. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF
J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
[TBL] [Abstract][Full Text] [Related]
16. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
[TBL] [Abstract][Full Text] [Related]
17. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
Zhang L; Sun JH; Hou ZH; Zhong BY; Yang MJ; Zhou GH; Wang WS; Huang P; Zhang S; Li Z; Zhu XL; Yan ZP; Ni CF
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):63-72. PubMed ID: 32965582
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
[TBL] [Abstract][Full Text] [Related]
19. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model.
Kim BK; Shim JH; Kim SU; Park JY; Kim DY; Ahn SH; Kim KM; Lim YS; Han KH; Lee HC
Liver Int; 2016 Jan; 36(1):92-9. PubMed ID: 25950442
[TBL] [Abstract][Full Text] [Related]
20. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization.
Prajapati HJ; Kim HS
PLoS One; 2017; 12(2):e0170750. PubMed ID: 28170405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]